📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

The impact of antiphospholipid antibodies/antiphospholipid syndrome on systemic lupus erythematosus. (2024)

First Author: Venturelli V

Attributed to: MICA: Development of PEGylated Domain I of beta-2-glycoprotein I as a new therapeutic agent for the antiphospholipid syndrome funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/rheumatology/kead618

PubMed Identifier: 38320586

Publication URI: http://europepmc.org/abstract/MED/38320586

Type: Journal Article/Review

Volume: 63

Parent Publication: Rheumatology (Oxford, England)

Issue: SI

ISSN: 1462-0324